Oral analgesics have an important place in the control of mild and moderate postoperative pain. Non-steroidal anti-inflammatory drugs appeared particularly useful for mild and moderate postoperative pain 1,2 until increased incidence of side-effects were reported 3, 4 . Concern about these side-effects have now tempered their popularity. Consequently paracetamol probably remains the most widely prescribed and "inherently safe" oral analgesic.
Within the literature, controversy exists with regard to the dose of paracetamol that can safely be prescribed in patients with alcoholic liver disease [5] [6] [7] . This is of concern, as there is a significant prevalence of alcohol-related chronic liver disease and paracetamol is widely available without prescription.
We describe a case of acute liver failure after therapeutic doses of paracetamol were prescribed for postoperative analgesia in a patient with chronic alcoholism, hepatitis C antibody-positive and biopsyproven cirrhosis.
CASE REPORT
A 40-year-old woman had an elective hysterectomy and bilateral salpingo-oophorectomy combined with an ileo-rectal anastomosis four months after a total colectomy for pan-colitis.
She had a past history of excessive alcohol intake, intravenous drug abuse and liver cirrhosis (demonstrated by liver biopsy at her previous laparatomy). Serology for hepatitis C antibody was positive. On examination she had no stigmata of chronic liver disease, in particular no hepatomegaly or ascites. Preoperatively, liver function biochemistry and coagulation studies were normal apart from a raised gamma-glutamyl-transferase, and marginally elevated alanine and aspartate amino-transferases.
Drugs used for general anaesthesia were thiopentone, fentanyl, atracurium and isoflurane. The patient was stable haemodynamically throughout the perioperative period. On the fifth postoperative day, the only abnormality in the liver function tests was an elevated gamma glutamyl transferase which in fact was reduced from that measured on admission (297 U/l vs 123 U/l). Postoperative pain management was provided by intravenous morphine using patientcontrolled analgesia. On day 6, postoperative analgesia was changed to oral paracetamol. She received paracetamol 9g in divided doses over the next three days ( Table 1) .
On the eighth postoperative day she became drowsy and developed abdominal pain and vomiting. On examination she had abdominal tenderness and a blood pressure of 75/50 mmHg. This period of hypotension lasted for twenty minutes and this resuscitation required 750 ml of colloid. No further hypotension was documented during the patient's admission. She was transferred to the high dependency unit. Investigations revealed a blood sugar of 1.8 mmol/l, grossly abnormal liver function tests and coagulation studies consistent with acute liver failure (Table 1) . There was no clinical evidence of sepsis and blood cultures were negative.
Serum paracetamol levels were considerably higher than expected from the intermittent oral doses she had received. Paracetamol was withheld, and N-acetyl-cysteine and intravenous dextrose were commenced. She made a steady recovery over the subsequent three weeks and was discharged from hospital.
DISCUSSION
A number of different initiating factors could explain this episode of acute liver failure. Potential hepatotoxic insults included anaesthetic agents, sepsis, hypotension, and paracetamol. The possibility of exposure to some hepatotoxin during admission that was not otherwise identified (alcohol, IV drugs), could not be excluded.
We cannot exclude the episode of hypotension and hepatic ischaemia as the cause of liver failure. However, the episode of hypotension was short-lived and responded rapidly to fluid resuscitation.
Exposure to paracetamol and its temporal relationship to the deterioration in the liver function tests, along with the toxic serum levels strongly suggests that paracetamol was at least partially responsible for the acute liver failure. Therapeutic ingestion of paracetamol in chronic alcoholics is reported to now be the single most frequent cause of acute liver failure in the United States 7 . The main characteristic of this disorder is striking elevation of serum aspartate aminotransferase, with levels exceeding 3000 U/l in most patients and 10,000 U/l in 20% of cases 8, 9 . The reported mortality is approximately 20% 10, 11 . The mechanism of the hepatotoxicity of paracetamol after therapeutic doses in patients with chronic liver disease remains unclear. Paracetamol is metabolized by two pathways in the liver (Figure 1 ). Most of the drug is conjugated to nontoxic compounds which are easily excreted. Less than 5% of the drug is metabolized by cytochrome P450 (mixed function oxidase) to produce a potentially toxic metabolite N-acetyl-p-benzoquinonimine (NAPQI). NAPQI has strong affinity for glutathione and cysteine residues 12 . After overdosage of paracetamol, excess production of NAPQI exerts its toxicity by two different mechanisms. NAPQI preferentially conjugates with glutathione to a nontoxic metabolite excreted in the urine, but liver stores of glutathione are rapidly depleted. Toxic oxygen radicals, normally deactivated by glutathione, then accumulate. In addition, NAPQI will bind with cysteine residues present in cellular proteins, which then interfere with hepatocellular enzymes and structural proteins, leading to hepatocellular death. N-acetylcysteine is effective in overdosage of paracetamol by either restoring depleted glutathione levels or by acting as an alternative substrate for NAPQI. Several factors have been implicated in the hepatotoxicity of therapeutic doses of paracetamol in patients with chronic liver disease. First, liver cirrhosis can impair the ability of the liver to conjugate drugs, thus increasing the amount of paracetamol metabolized to NAPQI 13 . Second, patients with cirrhosis, particularly secondary to alcohol, have reduced renal excretion of paracetamol and its metabolites 14 . Finally, chronic use of drugs (e.g. alcohol) which induce cytochrome P450 activity may significantly increase the proportion of paracetamol metabolized to NAPQI 13 . All of these mechanisms will increase NAPQI levels, with subsequent direct cellular damage and glutathione depletion. Serum paracetamol levels are useful in elucidating the relative importance of these factors in the development of acute liver failure in this setting.
Despite administration of doses normally regarded as safe, paracetamol accumulated over three days to a level considered toxic twelve hours after ingestion of an overdose of paracetamol. However the standard Rumack-Matthew nomogram 15 represents the hepatotoxic potential of paracetamol after a single large dose and it may not reflect the toxic potential of an accumulated serum level. There is no other currently available method for assessment of the toxic potential of paracetamol from the measured serum levels of paracetamol. Paracetamol remained detectable in the blood for 48 hours after the last dose of paracetamol. This suggests that paracetamol accumulation due to impaired metabolism and reduced clearance in chronic liver disease was a significant factor in the pathogenesis of acute liver failure.
This case highlights the potential for paracetamol to cause acute liver failure in patients with alcoholism and chronic liver disease. When prescribed to patients with chronic liver disease and a history of alcoholism, serum paracetamol levels and liver function tests should be monitored. Guidelines for the safe prescription of paracetamol have yet to be determined in alcoholics, patients with chronic liver disease and patients with a combination of alcoholism and chronic liver disease.
